Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12590
Title: The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.
Authors: Vella, Laura J;Andrews, Miles C;Pasam, Anupama;Woods, Katherine;Behren, Andreas;Cebon, Jonathan S
Affiliation: Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.
Issue Date: 3-Jul-2014
Citation: Oncoimmunology 2014; 3(7): e946367
Abstract: Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.
Internal ID Number: 25610732
URI: http://ahro.austin.org.au/austinjspui/handle/1/12590
DOI: 10.4161/21624011.2014.946367
URL: http://www.ncbi.nlm.nih.gov/pubmed/25610732
Type: Journal Article
Subjects: BRAF
MEK
T-lymphocytes
dendritic cells
melanoma
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.